The addition of pertuzumab to trastuzumab, in combination with chemotherapy, known as dual anti-HER2 therapy, has significantly enhanced the clinical benefit of neoadjuvant treatment in patients with HER2-positive breast cancer, revolutionizing the landscape of neoadjuvant therapy [3, 4]. The gene discussed is ERBB2; the disease is breast cancer.